Want to see GB:SUN full AI Analyst Report?
Top Page
Surgical Innovations
(LSE:SUN)
Select Model
Select Model
Rating:55Neutral
Price Target:
0.41 p
▼(-2.38% Downside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial performance (continued losses and soft revenue), partially offset by a low-debt balance sheet and a rebound to positive operating/free cash flow in 2025. Technically, the stock shows positive trend/momentum, but the extremely high RSI suggests the move may be overextended. Valuation is also a constraint because the negative P/E reflects lack of profitability.
Positive Factors
Conservative leverage
Very low leverage reduces interest and refinancing pressure, giving Surgical Innovations greater resilience if hospital purchasing weakens. The lighter debt burden also preserves flexibility to invest in product development, regulatory compliance, and distribution while the company works to restore profitability.
Negative Factors
Declining revenue
Recent top-line contraction indicates that product demand, pricing, mix, or hospital purchasing activity is not yet generating sustained growth. Prolonged revenue weakness can limit operating leverage, reduce reinvestment capacity, and make the path to durable profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Very low leverage reduces interest and refinancing pressure, giving Surgical Innovations greater resilience if hospital purchasing weakens. The lighter debt burden also preserves flexibility to invest in product development, regulatory compliance, and distribution while the company works to restore profitability.
Read all positive factors
Surgical Innovations (SUN) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£3.73M
Dividend YieldN/A
Average Volume (3M)642.78K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue Growth-3.68%
EPS Growth20.00%
CountryUK
Employees82
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding932,816,160
10 Day Avg. Volume1,660,776
30 Day Avg. Volume642,785
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.55
Price to Sales (P/S)0.36
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Surgical Innovations Business Overview & Revenue Model
Company Description
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and preci...
How the Company Makes Money
Surgical Innovations makes money primarily by selling minimally invasive surgical instruments and related devices to healthcare providers. Revenue is generated from the commercialisation of its product portfolio, which includes both disposable (si...
Surgical Innovations Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.48M | 11.60M | 11.95M | 12.01M | 11.34M | 9.13M |
| Gross Profit | 2.88M | 3.05M | 3.44M | 3.45M | 3.92M | 3.13M |
| EBITDA | -410.00K | -73.00K | -99.00K | 161.00K | 628.00K | 247.00K |
| Net Income | -1.16M | -895.00K | -1.94M | -509.00K | 264.00K | -456.00K |
Balance Sheet | ||||||
| Total Assets | 10.87M | 11.64M | 12.24M | 14.32M | 15.60M | 15.72M |
| Cash, Cash Equivalents and Short-Term Investments | 361.00K | 813.00K | 195.00K | 1.21M | 2.20M | 3.64M |
| Total Debt | 587.00K | 665.00K | 1.24M | 1.66M | 2.16M | 2.79M |
| Total Liabilities | 3.47M | 4.00M | 3.70M | 3.84M | 4.63M | 5.05M |
| Stockholders Equity | 7.40M | 7.65M | 8.54M | 10.48M | 10.96M | 10.66M |
Cash Flow | ||||||
| Free Cash Flow | 968.00K | 508.00K | -409.00K | -288.00K | -592.00K | -1.09M |
| Operating Cash Flow | 1.01M | 569.00K | -74.00K | 400.00K | 486.00K | -433.00K |
| Investing Cash Flow | -206.00K | -227.00K | -335.00K | -688.00K | -1.08M | -657.00K |
| Financing Cash Flow | 28.00K | 271.00K | -626.00K | -672.00K | -935.00K | -532.00K |
Surgical Innovations Technical Analysis
Negative
0.42
Price Trends
0.44
Negative
0.46
Negative
0.46
Negative
Market Momentum
>-0.01
Positive
0.92
Positive
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SUN, the sentiment is Negative. The current price of 0.42 is above the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.44, and below the 200-day MA of 0.46, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 0.92 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SUN.
Surgical Innovations Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | £8.28B | 17.23 | 12.25% | 2.99% | 2.17% | 27.33% | |
67 Neutral | £611.34M | 166.18 | 1.44% | 1.66% | 6.05% | -60.00% | |
55 Neutral | £3.73M | -4.00 | -15.47% | ― | -3.68% | 20.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | £43.34M | -2.13 | -38.29% | ― | ― | ― |
* Healthcare Sector Average
GB:SUN
Surgical Innovations
0.40
-0.18
-31.03%
GB:AMS
Advanced Medical Solutions
282.50
65.51
30.19%
GB:CREO
Creo Medical
9.65
-2.10
-17.87%
GB:SN
Smith & Nephew
989.00
-317.80
-24.32%
GB:TSP
TruSpine Technologies Plc
―
―
―
Surgical Innovations Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresRegulatory Filings and Compliance
Surgical Innovations Holds Revenue Steady, Completes MDR Transition and Brings in New CEO
Positive
Sep 30, 2026
Surgical Innovations reported broadly flat first-half 2026 revenue of £6.02 million, with margins modestly improved but profitability down as adjusted EBITDA slipped to £0.03 million. Net debt remained stable at £0.3 million and the...
Business Operations and StrategyExecutive/Board Changes
Surgical Innovations Names MedTech Veteran Alex Warnock as New CEO
Positive
Sep 28, 2026
Surgical Innovations Group plc has announced a leadership transition in which long-serving chief executive David Marsh will step down as CEO on 1 October 2026 to become a non-executive director, continuing to support the company through key relati...
Business Operations and StrategyFinancial Disclosures
Surgical Innovations Sets Date for Interim Results and Investor Briefing
Neutral
Sep 25, 2026
Surgical Innovations Group plc, an AIM-quoted designer and manufacturer of minimally invasive surgical technologies, markets resposable port access systems, instruments and retraction devices via its Elemental Healthcare subsidiary in the U.K. and...
Business Operations and Strategy
Surgical Innovations Secures Key NHS Minimally Invasive Surgery Framework Slot
Positive
Jul 7, 2026
Surgical Innovations Group’s wholly owned subsidiary Elemental Healthcare has secured a place on the NHS Minimally Invasive Surgery 3 framework agreement for an initial two-year term starting 10 August 2026. The award follows the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.